Effects of a change in recall period on reporting severe symptoms: an analysis of a pragmatic multisite trial.
Roshan PaudelAndrea C EnzingerHajime UnoChristine CroninSandra L WongDon S DizonHannah Hazard JenkinsJessica BianRaymond U OsarogiagbonRoxanne E JensenSandra A MitchellDeborah SchragMichael J HassettPublished in: Journal of the National Cancer Institute (2024)
A shorter recall period was associated with a reduction in the proportion of patients reporting moderate-severe symptoms. The optimal recall period may vary depending on whether electronic patient-reported outcomes are collected for active symptom management, as a clinical trial endpoint, or another purpose. ClinicalTrials.gov ID NCT03850912.
Keyphrases
- patient reported outcomes
- clinical trial
- study protocol
- end stage renal disease
- newly diagnosed
- phase ii
- chronic kidney disease
- adverse drug
- phase iii
- peritoneal dialysis
- randomized controlled trial
- prognostic factors
- sleep quality
- open label
- high intensity
- emergency department
- depressive symptoms
- electronic health record